

## SUPPLEMENTARY PROSPECTUS

**This Supplement (the "Supplement") comprises a supplementary prospectus relating to Guaranteed Investment Products 1 PCC Limited (the "Company") prepared in accordance with the Prospectus Rules of the Financial Conduct Authority (the "FCA") made under Section 73A of the Financial Services and Markets Act 2000. A copy of this Supplement has been delivered to the FCA and made available to the public in accordance with the Prospectus Rules.**

Each of the Directors of the Company, whose names appear in Part II of this Supplement, and the Company itself, accepts responsibility for the information contained in this Supplement. To the best of the knowledge of the Directors and the Company itself, who have taken all reasonable care to ensure that such is the case, the information contained in this Supplement is in accordance with the facts and does not omit anything likely to affect the import of such information. Santander UK plc accepts responsibility for the information contained in this Supplement in so far as it relates to Santander UK plc and declares that, having taken all reasonable care to ensure that such is the case, the information contained in this Supplement in so far as it relates to Santander UK plc, and for which Santander UK plc is responsible, is to the best of its knowledge, in accordance with the facts and contains no omission likely to affect its import.

---

### GUARANTEED INVESTMENT PRODUCTS 1 PCC LIMITED

*(a protected cell company incorporated with limited liability under the laws of Guernsey with registered number 42754)*

---

This Supplement is supplementary to, and must be read in conjunction with, each of: (i) the Registration Document dated 20 April 2016, as supplemented by a Supplementary Prospectus dated 10 May 2016, Supplementary Prospectus dated 15 July 2016, a Supplementary Prospectus dated 10 August 2016 and a Supplementary Prospectus dated 2 September 2016 (the "**2016 Registration Document**"); (ii) the Prospectus relating to the Protected Cell 268 Cell Shares, which comprises the 2016 Registration Document, the Securities Note dated 22 July 2016 and the Summary dated 22 July 2016 (the "**Protected Cell 268 Prospectus**"); and (iii) the Prospectus relating to the Protected Cell 269 Cell Shares, which comprises the 2016 Registration Document, the Securities Note dated 16 September 2016 and the Summary dated 16 September 2016 (the "**Protected Cell 269 Prospectus**" and together with the Protected 268 Prospectus the "**Prospectuses**" and each a "**Prospectus**"). Your attention is drawn, in particular, to the sections headed "Risk Factors" from page 6 of the 2016 Registration Document forming a part of each Prospectus and from page 3 of the relevant Securities Note forming a part of each Prospectus for a discussion of certain factors that should be considered in connection with an investment in Shares. Except where the context otherwise requires, (i) terms defined in the 2016 Registration Document shall have the same meaning when used in this document and (ii) terms defined in each of the Prospectuses have the same meaning in respect of the relevant Cell when used in this document.

This document is not an offer of securities for sale in the United States. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "**Securities Act**"), or any securities laws of any state of the United States and may not be offered or sold in the United States or to or for the account or benefit of US persons (as such terms are defined in Regulation S under the Securities Act) unless registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, such registration. The Shares will not be registered under the relevant securities laws of Canada, Australia or Japan. Accordingly, unless an exemption under such acts or laws is applicable, the Shares may not be offered, sold or delivered, directly or indirectly, in or into Canada, Australia or Japan.

9 November 2016

## **PART I: SIGNIFICANT NEW FACTOR**

### **Publication of the unaudited quarterly management statement of Santander UK Group Holdings plc for the six months ended 30 September 2016**

On 26 October 2016, Santander UK Group Holdings plc, the immediate parent company of Santander UK plc, published its unaudited Quarterly Management Statement for the nine months ended 30 September 2016 (the “**Quarterly Management Statement**”).

The content of Appendix 4 appearing on page 24 of such Quarterly Management Statement, which contains the unaudited consolidated financial information of Santander UK plc for the nine months ended 30 September 2016, is hereby incorporated in, and forms part of, the 2016 Registration Document and the Prospectuses.

A copy of the Quarterly Management Statement has been filed with the FCA by being submitted to the National Storage Mechanism and is available for inspection at the address referred to in Part J of the Registration Document and on the National Storage Mechanism at: <http://www.morningstar.co.uk/uk/NSM>.

The relevant section of the Quarterly Management Statement referred to above is also available at: <http://www.santander.co.uk/uk/about-santander-uk/investor-relations/santander-uk-plc/>.

## PART II: MATERIAL MISTAKE OR INNACCURACY

### Summary dated 22 July 2016 forming part of the Protected Cell 268 Prospectus

The Issuer has noted a material mistake in the Summary dated 22 July 2016 for the Protected Cell 268 Prospectus (the "**Protected Cell 268 Summary**"). The fourth paragraph of Element D.3 of the Protected Cell 268 Summary states that: "Investors should note that any Performance Return per Cell Share will be limited to a maximum amount of £0.16 per Cell Share." This statement contains a typographical error. The Performance Return per Cell Share is limited to a maximum of £0.13 per Cell Share, as correctly disclosed in the following sections of the Protected Cell 268 Prospectus:

- Element C.4 of the Protected Cell 268 Summary;
- the Risk Factors for the Securities Note dated 22 July 2016 for the Protected Cell 268 Prospectus (the "**Protected Cell 28 Securities Note**") under the Risk Factor entitled "*Performance Return Risk and Extent of Guaranteed Return*";
- the section entitled "Overview of the Offer" of the Protected Cell 268 Securities Note under the heading "Rights"; and
- Section C of the Protected Cell 268 Securities Note under the definition of "Performance Return" and the heading "INVESTMENT RETURN".

The Protected Cell 268 Summary is amended by deleting the fourth paragraph of Element D.3 and replacing it with the following:

"Investors should note that any Performance Return per Cell Share will be limited to a maximum amount of £0.13 per Cell Share. Any positive performance of the Index that would otherwise produce a Performance Return greater than this maximum amount will not be reflected in the Investment Return paid to investors."

## **PART III: ADDITIONAL INFORMATION**

### **1. Directors of the Company**

Gavin John Farrell  
John Reginald Le Prevost  
Paul Jonathan Meader

### **2. Significant Changes**

There has been no significant change in the financial or trading position of Santander UK plc and its subsidiaries since 30 September 2016 (being the date to which the most recent unaudited financial information was prepared).

### **3. Incorporation by Reference**

Where parts only of documents are incorporated by reference into this Supplement, any non-incorporated parts of such document are either deemed not relevant for an investor or are otherwise covered elsewhere in this Supplement.

If documents which are incorporated by reference themselves incorporate any information or other documents therein, either expressly or implicitly, such information or other documents will not form part of this Supplement for the purposes of the Prospectus Rules except where such information or other documents are specifically incorporated by reference or attached to this Supplement.

To the extent that there is any inconsistency between (a) any statement in this Supplement or any statement incorporated by reference into the 2016 Registration Document or the relevant Prospectus by this Supplement and (b) any other statement in or incorporated by reference in the 2016 Registration Document or the relevant Prospectus, the statements in (a) above will prevail.

### **4. Withdrawal rights**

Persons who have applied for Protected Cell 268 Cell Shares and Protected Cell 269 Cell Shares prior to publication of this Supplement and who wish to exercise their statutory withdrawal rights must do so by lodging a written notice of withdrawal (which shall include a notice sent by electronic mail to Paul.Withers@santanderam.co.uk or by facsimile to Santander ISA Managers Limited on 0845 603 2311), which must include the full name and address of the person wishing to exercise statutory withdrawal rights and, if such person is a member of CREST, the relevant participant ID and member account ID, with Santander ISA Managers Limited, 287 St. Vincent Street, Glasgow G2 5NB so as to be received no later than two business days after the date of this Supplement (i.e. by 5.30 p.m. on 11 November 2016). Notice of withdrawal given by any other means or which is deposited with or received by Santander ISA Managers Limited after expiry of such period will not constitute a valid withdrawal.

### **5. Document available for inspection**

Copies of this document (in addition to those listed as available for inspection at paragraph 1 of Part J of the 2016 Registration Document) may be inspected at the offices of Santander ISA Managers Limited at 287 St. Vincent Street, Glasgow G2 5NB, at the registered office of the Company during normal business hours of any business day (Saturdays, Sundays and public holidays excepted) and on the website of the Company at <http://www.jtcgroup.com/GIPL> until the close of the relevant Offer for Subscription.